MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells

Yong Lin; Xin Ge; Yiyang Wen; Zhu-Mei Shi; Qiu-Dan Chen; Min Wang; Ling-Zhi Liu; Bing-Hua Jiang; Yuan Lu

doi:10.18632/oncotarget.12268

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells

Yong Lin, Xin Ge, Yiyang Wen, Zhu-Mei Shi, Qiu-Dan Chen, Min Wang, Ling-Zhi Liu, Bing-Hua Jiang _ and Yuan Lu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:70857-70868. https://doi.org/10.18632/oncotarget.12268

Metrics: PDF 1970 views | HTML 2204 views | ?

Abstract

Yong Lin1,2, Xin Ge3,4, Yiyang Wen3, Zhu-Mei Shi3,5, Qiu-Dan Chen2, Min Wang3, Ling-Zhi Liu6, Bing-Hua Jiang3,6, Yuan Lu1

1Department of Laboratory Medicine, Huashan Hospital of Fudan University, Shanghai, China

2The Department of Clinical Laboratory, Central Laboratory, Jing’an District Centre Hospital of Shanghai, Huashan Hospital of Fudan University Jing’An Branch, Shanghai, China

3State Key Lab of Reproductive Medicine, Key Laboratory of Human Functional Genomics of Jiangsu Province, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, China

4Ninggao Personalized Medicine and Technology Innovation Center, Nanjing, China

5Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

6Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, United States of America

Correspondence to:

Bing-Hua Jiang, email: [email protected], [email protected]

Yuan Lu, email: [email protected]

Keywords: pancreatic adenocarcinoma, gemcitabine, miR-145, p70S6K1, chemoresistance

Received: May 09, 2016 Accepted: August 25, 2016 Published: September 27, 2016

ABSTRACT

Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic multimodality. Gemcitabine is the effective first-line drug in pancreatic adenocarcinoma treatment. However, gemcitabine chemoresistance of pancreatic adenocarcinoma cells has been a major obstacle for limiting its treatment effect. Our study found that p70S6K1 plays an important role in gemcitabine chemoresistance. MiR-145 is a tumor suppressor which directly targets p70S6K1 for inhibiting its expression in pancreatic adenocarcinoma, providing new therapeutic scheme. Our findings revealed a new mechanism underlying gemcitabine chemoresistance in pancreatic adenocarcinoma cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12268

Publication Alerts

Research Papers:

MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells

Abstract